A Secret Weapon For "3
All enrolled individuals who gained at the least one dose of zosuquidar or placebo all through induction had been monitored to the prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse gatherings were linked to the period of prolonged and substantial myelosuppression as is predicted with ind